Third Generation ALK Inhibitors - The Development of Lorlatinib and the Problems that Exist

Abstract

The malignant tumor with the greatest morbidity and fatality rates in the world today is lung cancer, from which Non-Small Cell Lung Cancer (NSCLC) accounts for 85%. To treat NSCLC, a variety of targeted therapeutics been developed in medicine. ALK inhibitors are one of them, and they're frequently used to treat NSCLC.The 3rd Generation of ALK inhibitors are now in use, starting with the initial 1st generation ALK inhibitors. Because the development of 1st and 2nd generation ALK inhibitors medicines has been motivated by a number of unfavorable factors. These medications include the 3rd generation ALK inhibitor lorlatinib as well as the 2nd and 3rd generation ALK inhibitors ceritinib and alectinib. Current study discusses the clinical features, effectiveness, and side effects of lorlatinib as well as its pharmacological effects.